▴ Fesoterodine is a muscarinic receptor antagonist that is rapidly and extensively converted to the active and more potent metabolite 5-hydroxymethyltolterodine. The drug is approved for once-daily oral administration in patients with overactive bladder syndrome (OAB).
▴ In two large, 12-week, randomized, double-blind, multicentre, phase III trials, oral fesoterodine 4 or 8 mg once daily improved the symptoms of OAB (frequency of micturition, urgency and urge incontinence) significantly more than placebo.
▴ Furthermore, significantly more patients receiving fesoterodine 4 or 8mg once daily had a positive response to therapy than those receiving placebo, as determined by a treatment questionnaire.
▴ Health-related quality of life was improved to a significantly greater extent in patients with OAB who received fesoterodine 4 or 8 mg once daily than in those who received placebo in a post hoc analysis of pooled data from the phase III trials.
▴ Fesoterodine 4 or 8 mg once daily was generally well tolerated in patients with OAB; the most frequent adverse event was dry mouth, which was generally mild to moderate in severity.
KeywordsOxybutynin Urge Incontinence Tolterodine Poor Metabolizers Extensive Metabolizers
Acknowledgements and Disclosures
The manuscript was reviewed by: A. Beaven, Department of Urology, North Shore Hospital, Auckland, New Zealand. H. Hashim, Bristol Urological Institute, Southmead Hospital, Bristol, UK; R. Millard, Department of Urology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
- 6.Pfizer Labs. Toviaz™ (fesoterodine fumarate) extended release tablets: prescribing information [online]. Available from URL: http://media.pfizer.com/files/products/uspi_toviaz.pdf [Accessed 2008 Dec 1]
- 7.European Medicines Agency. Toviaz 4 mg prolonged-release tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/toviaz/H-723-PI-en.pdf [Accessed 2008 Nov 27]
- 10.Malhotra B, Wood N, Holbrook M, et al. Thorough QT study to evaluate the effect of fesoterodine on cardiac repolarization [abstract no. P052]. Fundam Clin Pharmacol 2008; 22 (Suppl. 2): 68Google Scholar
- 14.Chapple C. Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase 2 controlled study [abstract no. 142 plus poster]. 34th Annual Meeting of the International Continence Society; 2004 Aug 23–27; ParisGoogle Scholar
- 15.Nitti V, Wiatrak M, Kreitman L, et al. Fesoterodine is an effective antimuscarinic for patients with overactive bladder: results of a phase 2 trial [abstract no. 306 plus poster]. 35th Annual Meeting of the International Continence Society; 2005 Aug 31–Sep 2; Montreal (QC)Google Scholar
- 20.Data on file, Pfizer, 2009Google Scholar